April 2026 Research Update

This month, the strongest new information came from a large Japanese registry that linked certain baseline measurements to a higher chance of serious outcomes over the next year. In that registry, a higher fraction of blood cells carrying the UBA1 change (VAF) and a higher starting prednisolone dose both predicted the combined outcome of death or becoming dependent on blood transfusions. This adds a clearer, patient-relevant picture that VEXAS severity can sometimes be reflected in measurable baseline factors, although it does not explain risk for every individual. [1]

The same registry also suggested that not all UBA1 variants behave the same way, because the UBA1 Met41Leu variant was linked to better survival after accounting for when disease started. Serious medical problems were common in routine follow-up, with Grade 3 or higher adverse events reported in 50% of patients within 1 year. Put together, these results emphasize that VEXAS often involves high medical risk, and that some genetic and baseline markers may help describe that risk more clearly in research and tracking. [1]

For patients and caregivers, this registry work mainly adds understanding about what might signal a harder disease course, rather than changing what anyone should do right now. It suggests that the amount of UBA1-mutated cells (VAF) and the level of steroid need at baseline may be meaningful markers for prognosis in groups of patients, and that the exact UBA1 variant may matter. What remains uncertain is how well these markers predict outcomes for a specific person, and whether they can reliably guide care decisions without further study. [1]

A multi-center imaging study reported that PET/CT scans often show inflammation-like signals in VEXAS, but the patterns are not specific enough to act like a single clear fingerprint of the disease. Bone marrow and lymph nodes were frequent sites of abnormal uptake, and scans often showed several organs involved. This helps set expectations: PET/CT may be better at mapping where inflammation might be happening than at confirming a diagnosis by itself. [2]

The study also found that scans tended to look more widespread during active disease than during remission, but many scans stayed abnormal even when patients were thought to be in remission. For example, 90% of scans done during presumed remission still had abnormalities, often in bone marrow. In plain language, this raises the possibility that some inflammation may continue quietly even when symptoms seem controlled, though the study did not show what those persistent scan findings mean for future symptoms or outcomes. [2]

For patients, this imaging research mainly matters as background information about testing and monitoring, not as a new proven tool that everyone needs. It suggests PET/CT findings may not fully "normalize" even when someone feels better, which can be confusing if imaging is used during follow-up. What remains uncertain is whether persistent PET/CT abnormalities during remission predict flare-ups, organ problems, or the need for different treatments, because those links were not established here. [2]

This month had 2 single-patient reports that underline how wide-ranging and serious VEXAS complications can be, especially in people receiving immune-suppressing medicines. One report centered on a severe soft-tissue infection that progressed to septic shock, and another described kidney inflammation with heavy protein loss in the urine alongside blood count problems. Together, these cases reinforce that VEXAS can involve both infection risk and organ involvement, but they cannot tell how often these events happen. [3] [4]

In the infection case, the bacteria was initially misidentified on routine testing and later clarified with whole-genome sequencing, and the patient recovered after leg amputation and antibiotics. The main message is not about a typical VEXAS infection, but about how severe infections can arise during immune suppression and how accurate identification of the germ can matter in complex situations. Because this is one person, it is best read as an example of what can occur rather than a general expectation. [3]

In the kidney case, a man with a UBA1 Met41Val change had crescentic glomerulonephritis (a severe form of kidney inflammation) and later developed severe pancytopenia (low blood counts). He improved at first with corticosteroids, tocilizumab, and mycophenolate mofetil, but later needed azacitidine because of worsening blood counts, and transplant was considered. The report highlights that kidney involvement can occur even when common vasculitis blood tests are negative, and it stresses the importance of genetic testing for confirming VEXAS in complex presentations. [4]

For patients and caregivers, these reports mainly serve as real-world examples of the kinds of complications doctors watch for in VEXAS, rather than providing evidence that any specific complication is likely. They show that serious infections may occur during immune-suppressing treatment and that VEXAS can sometimes involve the kidneys in addition to blood and inflammation problems. What remains uncertain is how common these issues are and which patients are at highest risk, because case reports cannot answer frequency or predictability. [3] [4]